Advertisement
Advertisement
EXEL
Exelixis Inc
54.15
USDSponsored
-1.82
-3.26%
Jul 31, 10:06 UTC -4
Open
EXEL Earnings Reports
Positive Surprise Ratio
EXEL beat 34 of 42 last estimates.
81%
Next Report
Next Week
Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
$648.67M
/$0.80
Implied change from Q1 26 (Revenue/ EPS)
+6.20%
/+1.27%
Implied change from Q2 25 (Revenue/ EPS)
+14.15%
/+23.08%
Exelixis Inc earnings per share and revenue
On May 05, 2026, EXEL reported earnings of 0.79 USD per share (EPS) for Q1 26, beating the estimate of 0.71 USD, resulting in a 10.07% surprise. Revenue reached 610.81 million, compared to an expected 617.30 million, with a -1.05% difference. The market reacted with a +9.64% price change (close before vs. close after earnings).
Looking ahead to Q2 26, -- analysts forecast an EPS of 0.80 USD, with revenue projected to reach 648.67 million USD, implying an increase of 1.27% EPS, and increase of 6.20% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Alnylam Pharmaceuticals, Inc.
Report Date
Jul 30, 2026 For Q2 26
Estimate
$1.58
Actual
$1.84
Surprise
+16.03%
Moderna, Inc. Common Stock
Report Date
Jul 31, 2026 For Q2 26
Estimate
-$2.12
Actual
-$1.97
Surprise
+7.28%
Illumina Inc
Report Date
Jul 30, 2026 For Q2 26
Estimate
$1.25
Actual
$1.31
Surprise
+4.74%
Guardant Health, Inc. Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.41
Actual
-$0.42
Surprise
-0.02%
PTC Therapeutics, Inc.
Report Date
Jul 30, 2026 For Q2 26
Estimate
$0.41
Actual
$0.92
Surprise
+122.65%
Agios Pharmaceuticals, Inc.
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$1.70
Actual
-$1.69
Surprise
+0.66%
Vericel Corporation
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.02
Actual
$0.04
Surprise
+239.37%
Wave Life Sciences Ltd. Ordinary Shares
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.31
Actual
-$0.34
Surprise
-8.94%
Pharming Group N.V. ADS, each representing 10 ordinary shares
Report Date
Jul 30, 2026 For Q2 26
Estimate
$0.02
Actual
$0.02
Surprise
-0.50%
Phathom Pharmaceuticals, Inc. Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.25
Actual
$0.00
Surprise
+100.00%
FAQ
What were Exelixis Inc's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Exelixis Inc reported EPS of $0.79, beating estimates by 10.07%, and revenue of $610.81M, -1.05% below expectations.
How did the market react to Exelixis Inc's Q1 2026 earnings?
The stock price moved up 9.64%, changed from $44.42 before the earnings release to $48.70 the day after.
When is Exelixis Inc expected to report next?
The next earning report is scheduled for Aug 05, 2026.
What are the forecasts for Exelixis Inc's next earnings report?
Based on --
analysts, Exelixis Inc is expected to report EPS of $0.80 and revenue of $648.67M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement